NCT02965053View on ClinicalTrials.gov

A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

August 31, 2018

Study Completion Date

August 31, 2018

Conditions
Hyperphosphatemia
Interventions
DRUG

EOS789

DRUG

Placebo

DRUG

Renvela

Trial Locations (1)

Unknown

Indianapolis

Sponsors
All Listed Sponsors
lead

Chugai Pharmaceutical

INDUSTRY